Volume 9

Issue 3

Article 5

2001

Genotyping 5,10-methylenetetrahydrofolate reductase for patients
with coronary artery disease in Southern Taiwan

Follow this and additional works at: https://www.jfda-online.com/journal

Recommended Citation
Kou, M-C.; Wang, L.; Liang, K.-J.; and Wu, M.-J. (2001) "Genotyping 5,10-methylenetetrahydrofolate
reductase for patients with coronary artery disease in Southern Taiwan," Journal of Food and Drug
Analysis: Vol. 9 : Iss. 3 , Article 5.
Available at: https://doi.org/10.38212/2224-6614.2789

This Original Article is brought to you for free and open access by Journal of Food and Drug Analysis. It has been
accepted for inclusion in Journal of Food and Drug Analysis by an authorized editor of Journal of Food and Drug
Analysis.

173
Journal of Food and Drug Analysis, Vol. 9, No. 3, 2001, Pages 173-177

Genotyping 5,10-Methylenetetrahydrofolate Reductase for
Patients with Coronary Artery Disease in Southern Taiwan
MEI-CHUN KOU, LISU WANG, KUEI-JUNG LIANG AND MING-JIUAN WU*
Department of Food Health, Chia-Nan University of Pharmacy and Science
60 Erh-Jen Road, Section 1, Jen Te, 717 Tainan, Taiwan, R. O. C.
(Received: September 16, 2000; Accepted: May 7, 2001)

ABSTRACT
Hyperhomocysteinaemia has been identified as a risk factor for cerebrovascular, peripheral vascular and coronary heart disease
(CAD). Individuals with homozygous MTHFR (5,10-Methylenetetrahydrofolate reductase) mutation have significantly elevated plasma
homocysteine levels. Two common mutations in MTHFR (MTHFR 677CT and MTHFR 1298AC) may represent an important genetic risk factor in vascular disease. The aim of this research was to investigate these two point mutations of MTHFR for CAD patients and
non-CAD controls in Southern Taiwan by PCR-restriction fragment length polymorphism assay. We found that the distribution of the
homozygous mutation for MTHFR677 was higher in 54 CAD patients than in 55 non-CAD subjects (11.1% versus 3.6%, P = 0.275). On
the other hand, the frequency of MTHFR 1298CC in CAD patients was similar to that of control subjects (P = 1.000). This may suggest
there is a trend toward an increased risk of coronary heart disease for individuals that have a 677TT genotype in the Taiwanese population.
Finally, the frequency of homozygosity for the two MTHFR common mutations was still low in CAD cases. There may not be an appreciable association of MTHFR mutation to cardiovascular disease in Taiwan. Perhaps a further study including assessment of plasma concentrations of homocysteine, folate and vitamin B12 would be needed to better clarify the relationship between MTHFR polymorphisms
and the occurrence of vascular disease.
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INTRODUCTION
Hyperhomocysteinaemia, defined as a mildly elevated
plasma homocysteine (Hcy) level, is associated with cardiovascular diseases. An elevated level of Hcy has been implicated in the role of promoting growth of vascular smooth
muscle cells along with inhibiting endothelial cell growth.
Additional putative mechanisms of thrombosis in hyperhomocystinemia include increased platelet adhesiveness,
enhanced LDL deposition in the arterial wall, and direct activation of the coagulation cascade (1). Hyperhomocysteinaemia has been identified as a risk factor for cerebrovascular,
peripheral vascular and coronary artery disease (CAD)(2-5).
Homocysteine is a sulphur amino acid formed by
demethylation of the essential amino acid methionine, and it
can be degraded by cystathionine- β -synthase (CBS).
Alternatively, Hcy may be remethylated to methionine, a
process requiring the sufficient function of several enzymes.
Methionine synthase (MS), one of the key enzymes, catalyzes the remethylation of Hcy in the presence of methylcobalamin (Me-Cbl) and 5-methyl-tetrahydrofolate (MeTHF). Formation of Me-THF requires both an adequate supply of reduced folate and proper function of methylenetetrahydrofolate reductase (MTHFR) (6) . Dysfunctional
MTHFR caused by genetic mutations or inadequate amount
of reduced folate may therefore result in elevated concentrations of Hcy(7). The plasma concentrations of Hcy varied
* Author for correspondence. Tel: 06-2664911 ext. 220 ext. 193;
Fax: 06-2666411; E-mail: imwu@mail.chna.edu.tw

among different populations, ages, sexes, diet habits and
individual health conditions(8).
Two common point mutations have been found in
MTHFR. The first identified polymorphism (677CT), a
missense mutation in exon 4 of the MTHFR gene found by
Frosst, is a cytosine (C) to thymine (T) substitution at
nucleotide 677, which converts an alanine (A) to a valine
(V)(9). Reduction in activity or thermolability of MTHFR has
been associated with the heterozygous or homozygous 677T
genotype. Homozygotes for the 677T allele are predisposed
to hyperhomocysteinemia by the 50% decrease of MTHFR
activity, particularly in the context of suboptimal folate status
(7). A high proportion of people with the 677T homozygous
genotype show a satisfactory Hcy lowing response to modest
daily folate supplements in the range 100-200 µg/d (10).
Recently, a second common polymorphism in the MTHFR
gene has been reported that results in a glutamate-to-alanine
conversion (1298AC)(11). This polymorphism also results
in diminished enzyme activity, elevated Hcy concentration,
and decreased folate concentration in plasma(12). Therefore,
these two common mutations (MTHFR677C  T and
1298AC) may represent an important risk factor in vascular diseases(13).
Recently, there have been several reports on the correlation between MTHFR polymorphism and vascular diseases
in Taiwan, published by research teams from National
Taiwan University Hospital, the Veterans Hospital and
National Cheng-Kung University Hospital(14-16). No report
on the prevalence of MTHFR 1298AC or the relationship
between MTHFR 1298AC and MTHFR677CT in the
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Taiwanese population has been found so far. The aim of this
study was to use PCR and restriction fragment length polymorphism (RFLP) to screen the prevalence of MTHFR
1298AC and MTHFR677CT polymorphisms in CAD
patients and healthy subjects in the Tainan area and to find
out the association between cardiovascular disease and the
genotypes. The results will form the basis for future studies,
including assessment of plasma concentrations of Hcy, folate
and vitamin B12 in order to better clarify the relationship
between MTHFR polymorphisms and occurrence of vascular
disease.

MATERIALS AND METHODS
I. Subjects
Blood was collected from fifty-four patients with CAD
from the internal cardiovascular department at Chi-Mei
Hospital in Tainan. The average age of the group was 64.3,
and consisted of forty-one males and thirteen females.
Control samples were randomly collected from fifty-five
patients with non-CAD or non-vascular diseases history at
Chi-Mei Hospital. Their average age was 66.7, and consisted
of thirty-one males and twenty-four females.
II. Isolation of Genomic DNA
Genomic DNA was isolated using the QIAamp DNA
Blood Mini Kit (QIAGEN GmbH, Hilden, Germany) from
blood drawn from CAD patients and control subjects. The
purity, size and concentration of isolated DNA were measured by A260, A280 and agarose gel electrophoresis.
III. PCR Amplification and MTHFR Polymorphisms
Detection
The MTHFR677CT mutation alters an alanine into a
valine residue, creating a HinfI site. The presence of this
mutation was analyzed according to established procedures (9) . The primers for PCR were 5’-TGAAGGAGAAGGTGTCTGGGGGA-3’ (exonic) and 5’-AGGACGGTGCGGTGAGAGTG-3’ (intronic). The PCR was carried
out in a total volume of 50 µL, containing 10 mM Tris-HCl,
50 mM KCl, 0.1% TritonX-100, 200 µM dNTP, 1.5 mM
MgCl2, 100 ng genomic DNA, 10 pmol of each primer, and 2
units Taq DNA polymerase (Promega, Wisconsin, USA).
PCR parameters were as follows: an initial denaturation step
of 4 min at 94˚C, followed by 30 cycles of 94˚C/60 s,
55˚C/60 s, and 72˚C/60 s, and a final cooling at 15˚C.
The PCR amplified products were then cleaned by a
GFX TM PCR DNA Kit (Amersham Pharmacia Biotech,
Uppsala, Sweden) to remove excess primers. Five µL purified PCR fragments were digested with 1 µL (10 U/mL)
HinfI at 37˚C for 2 hours, followed by adding 1 µL (10
U/mL) HinfI and reacted for another 2 hours in order to completely digest the DNA. The restriction digested fragments
were then separated on 4% agarose gel electrophoresis.

The MTHFR1298AC mutation alters a glutamate into
an alanine residue, abolishing a MboII site. The
MTHFR1298A C mutation was analyzed according to
established procedures(11). The PCR was carried out in a total
volume of 50 µL, containing 10 pmol of forward primer 5’CTTTGGGGAGCTGAAGGACTACTAC-3’ and 10 pmol of
the reverse primer 5’-CACTTTGTGACCATTCCGGTTTG’3’, 10 mM Tris-HCl, 50 mM KCl, 0.1% TritonX100, 200 µM dNTP, 1.5mM MgCl2, 100 ng genomic DNA,
and 2 units Taq DNA polymerase (Promega, Wisconsin,
USA). PCR parameters were a 2-min denaturation step at
92˚C followed by 35 cycles of 92˚C/60 s, 51˚C/60 s, and
72˚C/60 s, and a final cooling at 15˚C.
The PCR amplified products were then cleaned by a
GFX TM PCR DNA Kit (Amersham Pharmacia Biotech,
Uppsala, Sweden) to remove excess primers. Five µL purified PCR fragments were digested with 1 µL (10 U/µL)
MboII at 37˚C for 2 hours. The restriction digested fragments
were then separated on 4% agarose gel electrophoresis.
IV. Agarose Gel Electrophoresis
The restriction digested products were separated on 4%
agarose gel made of Nusive 3:1 agarose gel (FMC, Maine,
USA) and ethidium bromide. The running condition was 100
volts for 1.5 hours at 4˚C. The gel was then visualized under
UV and the imagine was captured and stored by an Uvi system.
V. Statistics
Statistical analyses were performed using SPSS window-10.0. Comparisons were analyzed by the Chi-square test
and the Fisher exact probability test.

RESULTS AND DISCUSSION
Genomic DNA was isolated from the blood of CAD
patients and control subjects by a QIAamp DNA Blood Mini
Kit. The isolated DNA was then analyzed on 0.5% agarose
gel electrophoresis. Most of the molecular weights of the
DNA were more than 15 kb, although some appeared to contain tailing. Overall, the effect of purification was good and
the tailing might be due to pipeting shearing or gel overloading.
The purified genomic DNA was then amplified by PCR
as described in Materials and Methods. The amplified products were then analyzed by a 2% agarose gel electrophoresis
and the molecular weights were 198 bp and 163 bp for
MTHFR677CT and MTHFR1298AC, respectively.
The MTHFR677CT alters an alanine into a valine
residue, creating a HinfI site. After restriction analysis of the
198-bp PCR fragment with HinfI, we expected and observed
the following: the MTHFR677+/+ (+ indicates wild type)
gives a 198-bp band, whereas MTHFR677-/- (- indicates
mutant) results in a 175-bp band, and MTHFR677+/- generates 198-bp and 175-bp bands (as shown in Figure 1). The
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Figure 1. Restriction enzyme analysis for the alanine to valine substitution. The substitution creates a HinfI recognition sequence which
digest the 198 bp fragment into 175 and 23 bp fragments; the latter fragment has been run off the gel. All three possible genotypes are shown.
AC
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Figure 2. Restriction enzyme analysis for the glutamine to alanine substitution. The substitution abolishes an MboII recognition site.
Digestion of the 163 bp fragment of the 1298 CC gives four fragments,
of 84, 31,30 and 18 bp, whereas the 1298AA genotype results in five
fragments, of, namely, 56, 31, 30, 28, and 18 bp. The 18 bp fragment
has been run off the gel. All three possible genotypes are shown.

MTHFR1298AC mutation alters a glutamate into an alanine residue, abolishing an MboII site. After restriction
analysis of the 163-bp PCR fragment with MboII, we expected and observed the following: the MTHFR1298+/+ gives 5
fragments, namely 56, 31, 30, 28 and 18-bp fragment, whereas MTHFR1298-/- results in 4 fragments, namely 84, 31, 30
and 18-bp fragment, and MTHFR1298+/- generates 6 fragments, namely 84, 56, 31, 30, 28 and 18-bp fragment (as
shown in Figure 2).
Because each individual has both a MTHFR677 and a
MTHFR1298 genotype, the associations between disease and
allelic variants of one polymorphism are first reported so that
their effects are described independently of allelic variants of
the other polymorphism. Among the 54 cases diagnosed with
CAD and 55 matched controls, we found the MTHFR677-/genotype present among 5 (11.1%) cases and 2 (3.6%) controls, the MTHFR677+/- genotype among 19 (35.2%) cases
and 18 (32.7%) controls, and the MTHFR 677+/+ allele
among 29 (53.7%) cases and 35 (63.6%) controls. It seemed
that the occurrence of MTHFR677-/- allele was a little bit

higher in CAD patients than in control, indicating that subjects with homozygous mutations may be prone to cardiovascular diseases. However, the association between disease and
the allelic variants analyzed by the Chi-square test and the
Fisher exact probability test showed an insignificant correlation (P=0.275). There have been several reports on the correlation between MTHFR polymorphisms and CAD in Taiwan
(14-16). A report published by National Taiwan University
Hospital showed the frequency of the MTHFR677-/- genotype for CAD patients and control subjects was similar, both
were 10%(14); while a slightly higher frequency can be found
in CAD (6.7%) than in the control (4.6%) according to a
National Chen-Kung University Hospital report(16). The frequency of the MTHFR677-/- genotype in CAD patient in this
study (11.1%) was a little bit higher than previous reports.
Generally speaking, distribution of MTHFR677-/- genotype
varied significantly among different populations. The worldwide survey of 881 unrelated individuals published by
Schneider et al. showed that the MTHFR677-/- genotype frequency in Africans was the lowest at 0%, Europeans at 7.4%,
and Asia populations (including Chinese, Mongolia, Vanuatu
and Indonesia) varying from 1.5% to 12.8%(19). Another
report on 114 unselected French Canadians showed the
MTHFR 677-/- genotype frequency was 12%(9). Another
report showed that the MTHFR677-/- genotype frequency for
European, Middle East and Japanese populations was from
12 to 15 %(17). Our report on the frequency of MTHFR677-/genotype for Southern Taiwanese is higher than that of
Africans but lower than European, Middle East or Japanese
populations.
We further analyzed the MTHFR1298 AC polymorphism among the same samples. We found that the
MTHFR1298-/- allele present among 2 (3.7%) cases and 3
(5.45%) controls, the MTHFR1298+/- genotype among 16
(29.6%) cases and 16 (29.1%) controls, and the
MTHFR 1298 +/+ allele among 36 (66.7%) cases and 36
(65.5%) controls. The frequency of MTHFR1298-/- genotype
reported here was much lower than that of Dutch (11) or
Canadians(12) (10%). From the above results, we concluded
that the association between CAD and MTHFR677-/- genotype (P=0.275) is insignificant and no association between
CAD and MTHFR1298-/- can be found (P=1).
We next investigated the distribution of the joint
effects of the two polymorphisms as shown in Table 1.
Here we found the genotype frequency for normal allele
(MTHFR677+/+, MTHFR1298+/+) is the highest, about 35%,
among both the CAD and the control; followed by
heterozygous MTHFR677 and normal MTHFR1298
(MTHFR677+/-, MTHFR1298+/+), about 24%; and followed
by normal MTHFR677 and heterozygous MTHFR1298
(MTHFR677+/+, MTHFR1298+/-), about 19%. The trends
were compatible with the report of Skibola(18). The frequency of double heterozygous mutations (MTHFR 677 +/-,
MTHFR1298+/-) is higher in CAD patients than in the control
(13% vs. 7.3%). It has been shown that the enzyme activity of
double heterozygous mutations is similar to that of homozygous mutation (MTHFR677-/-) and is only 50-60% of normal
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Table 1. Frequency of the MTHFR 677and MTHFR 1298 genotypes in coronary artery disease patients and controls
CAD n(%) total: 54 (100%)
Control n(%) total: 55 (100%)
MTHFR677+/MTHFR677-/MTHFR677+/+
MTHFR677+/MTHFR677-/MTHFR677+/+
1298
MTHFR
+/+
18(33.3%)
12(22.2%)
6(11.1%)
20(36.3%)
14(25.5%)
2(3.6%)
9(16.7%)
7(13.0%)
0(0%)
12(21.8%)
4(7.3%)
0(0%)
MTHFR1298+/MTHFR1298-/2(3.7%)
0(0%)
0(0%)
3(5.5%)
0(0%)
0(0%)

genotype(12). Furthermore, we were unable to identify any
subject with double homozygous mutations (MTHFR677-/-,
MTHFR1298-/-) in CAD patients or normal control. Similar
results have been reported in Dutch(11) , Canadian(12), and
British(18) populations.
The above results may indicate: 1) The frequency of
genotype of MTHFR677-/- or MTHFR1298-/- is lower in the
Taiwanese population than in most other populations.
Therefore, although the distribution of MTHFR677-/- was
higher in CAD patients than in the control, the association
between CAD and MTHFR677-/- is insignificant. The distribution of MTHFR1298-/- genotype is similar between CAD
patients and the control, suggesting that Southern Taiwanese
with the MTHFR677-/-, not the MTHFR1298-/-, genotype may
be at an increased risk for cardiovascular disease. 2) The
patients we screened may carry other genetic mutations such
as cystathionine-β-synthase (CBS) and methionine synthase
(MS), which may also cause hyperhomocysteinaemia. 3)
MTHFR mutation exerts its influence on CAD through the
action of Hcy. However, the plasma Hcy level is not only
influenced by the genetic variations, but also by non-genetic
factors such as diet. The nutritional compensation may make
a substantial difference in Hcy levels among those with
MTHFR677-/- genotype. It has been known that in addition to
hyperhomocysteinaemia, high blood pressure, hypercholesterolaemia, diabetes or smoking are risk factors cardiovascular disease. As the MTHFR mutations account only for a
fraction of the risk factors, a much larger sample size might
be necessary to demonstrate the relationship between
MTHFR polymorphisms and occurrence of vascular disease.
Perhaps a long-term study of plasma concentrations of Hcy
and the intake of folate and vitamin B12 would be needed to
clarify the association between MTHFR polymorphisms and
CAD.
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